Provectus Biopharmaceuticals, Inc. (PVCT) stock
PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Provectus Biopharmaceuticals cash
Cash and short-term investments held at the end of each period.
Provectus Biopharmaceuticals's cash was $1.16M at Jun 30, 2026. For fiscal 2025 it was $251.29K, down 18.3% from the year before. Over ten years it grew -33.2% a year on average. The highest annual figure on record is $17.39M in fiscal 2014.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $251.29K | -18.3% |
| FY2024 | Dec 31, 2024 | $307.44K | +301.5% |
| FY2023 | Dec 31, 2023 | $76.58K | +254.4% |
| FY2022 | Dec 31, 2022 | $21.61K | -96.8% |
| FY2021 | Dec 31, 2021 | $682.98K | +602.4% |
| FY2020 | Dec 31, 2020 | $97.23K | -83.5% |
| FY2019 | Dec 31, 2019 | $590.71K | +1058.6% |
| FY2018 | Dec 31, 2018 | $50.99K | -51.7% |
| FY2017 | Dec 31, 2017 | $105.50K | -90.9% |
| FY2016 | Dec 31, 2016 | $1.17M | -91.8% |
| FY2015 | Dec 31, 2015 | $14.18M | -18.5% |
| FY2014 | Dec 31, 2014 | $17.39M | +10.8% |
| FY2013 | Dec 31, 2013 | $15.70M | +1184.8% |
| FY2012 | Dec 31, 2012 | $1.22M | -84.1% |
| FY2011 | Dec 31, 2011 | $7.71M | -4.7% |
| FY2010 | Dec 31, 2010 | $8.09M | +149.8% |
| FY2009 | Dec 31, 2009 | $3.24M | +15.8% |
| FY2008 | Dec 31, 2008 | $2.80M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.16M | +199.8% |
| Q1 FY2026 | Mar 31, 2026 | $223.88K | -42.7% |
| Q4 FY2025 | Dec 31, 2025 | $251.29K | -18.3% |
| Q3 FY2025 | Sep 30, 2025 | $72.48K | -61.3% |
| Q2 FY2025 | Jun 30, 2025 | $385.93K | +1204.7% |
| Q1 FY2025 | Mar 31, 2025 | $390.44K | +2064.9% |
| Q4 FY2024 | Dec 31, 2024 | $307.44K | +301.5% |
| Q3 FY2024 | Sep 30, 2024 | $187.46K | -49.0% |
| Q2 FY2024 | Jun 30, 2024 | $29.58K | -83.2% |
| Q1 FY2024 | Mar 31, 2024 | $18.04K | -47.2% |
| Q4 FY2023 | Dec 31, 2023 | $76.58K | +254.4% |
| Q3 FY2023 | Sep 30, 2023 | $367.25K | +447.9% |
| Q2 FY2023 | Jun 30, 2023 | $176.01K | +108.9% |
| Q1 FY2023 | Mar 31, 2023 | $34.15K | -80.3% |
| Q4 FY2022 | Dec 31, 2022 | $21.61K | -96.8% |
| Q3 FY2022 | Sep 30, 2022 | $67.03K | -73.6% |
| Q2 FY2022 | Jun 30, 2022 | $84.27K | +77.8% |
| Q1 FY2022 | Mar 31, 2022 | $173.61K | -50.4% |
| Q4 FY2021 | Dec 31, 2021 | $682.98K | +602.4% |
| Q3 FY2021 | Sep 30, 2021 | $254.08K | -74.2% |
| Q2 FY2021 | Jun 30, 2021 | $47.41K | -96.8% |
| Q1 FY2021 | Mar 31, 2021 | $349.77K | +63.6% |
| Q4 FY2020 | Dec 31, 2020 | $97.23K | -83.5% |
| Q3 FY2020 | Sep 30, 2020 | $986.52K | +126.9% |
| Q2 FY2020 | Jun 30, 2020 | $1.48M | +12.0% |
| Q1 FY2020 | Mar 31, 2020 | $213.74K | -87.9% |
| Q4 FY2019 | Dec 31, 2019 | $590.71K | +1058.6% |
| Q3 FY2019 | Sep 30, 2019 | $434.79K | +87.5% |
| Q2 FY2019 | Jun 30, 2019 | $1.32M | +913.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.77M | +624.3% |
| Q4 FY2018 | Dec 31, 2018 | $50.99K | -51.7% |
| Q3 FY2018 | Sep 30, 2018 | $231.92K | +11.3% |
| Q2 FY2018 | Jun 30, 2018 | $130.63K | -88.4% |
| Q1 FY2018 | Mar 31, 2018 | $244.10K | -44.1% |
| Q4 FY2017 | Dec 31, 2017 | $105.50K | -90.9% |
| Q3 FY2017 | Sep 30, 2017 | $208.28K | -96.0% |
| Q2 FY2017 | Jun 30, 2017 | $1.13M | – |
| Q1 FY2017 | Mar 31, 2017 | $436.95K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.17M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.18M | – |
See a number that looks wrong?